Hollar will succeed Mike Kaufmann, who has been Dublin, Ohio–based Cardinal Health’s CEO for the past five years. The CEO transition comes as Cardinal Health continues efforts to refocus its Medical business after the $1 billion sale of its Cordis business last year.
“This is a transformational period at Cardinal Health, and I am humbled to have the opportunity to lead a business that plays such a vital role in the healthcare ecosystem,” Hollar said in a news release.
Cardinal Health independent board chairperson Gregory Kenny described Kaufmann as a “tremendous leader during his tenure at Cardinal Health, helping the company navigate a period of unprecedented challenges, directing strategic investments for growth and innovation, and cultivating an inclusive and vibrant workforce culture.”
“We look forward to leveraging Jason’s broad executive experience and are confident in his ability to lead Cardinal Health on a path to long-term growth,” Kenny said.
Filed Under: Drug Discovery and Development